8:00AM GeoPharma subsidiary receives FDA approval for Mucotrol (GORX) 4.43: Co announced that Belcher Pharmaceuticals, a wholly-owned subsidiary of GeoPharma, has received approval from the FDA for Mucotrol, a prescription product for the management of oral mucositis / stomatitis. It is estimated that approximately 300k cancer patients in the U.S. suffer from mucositis associated with cancer treatments. Based on this, the estimated U.S. oncology market potential for Mucotrol sales are between $75 mln and $300 mln per annum and the estimated global market is between $250 mln and $1 bln per annum.